ReviewCold antibody autoimmune hemolytic anemias
Introduction
The immune hemolytic anemias are classified as indicated in Table 1.1 This classification divides these disorders into distinctive categories which have differing clinical manifestations, prognosis and therapy, as indicated in Table 2. The cold antibody autoimmune hemolytic anemias (AIHAs) are primarily comprised of cold agglutinin syndrome (CAS) and paroxysmal cold hemoglobinuria (PCH) but, in addition, there are unusual instances in which patients satisfy the serologic criteria of both warm antibody AIHA and CAS. Such cases are designated as combined cold and warm AIHA or “mixed AIHA.”
These disorders are diagnosed on the basis of characteristic serologic reactions. The majority of cases of AIHA are mediated by warm-reactive autoantibodies, i.e., antibodies displaying optimal reactivity with human RBC at 37 °C and which are usually of the IgG immunoglobulin class. In contrast, CAS is generally caused by IgM autoantibodies which exhibit maximal reactivity at 4 °C.
The causative in PCH antibody is an IgG immunoglobulin with specificity that differs from that found in CAS. The antibody is best detected in vitro by its ability to cause hemolysis of normal RBC in a two-step procedure, which requires incubation in the cold followed by incubation at 37 °C in the presence of complement.
AIHA is designated as “idiopathic” if it is unassociated with any demonstrable underlying disease. In contrast, AIHA is categorized as “secondary” if it is associated with an additional disorder and there is reason to suspect that the association is not merely fortuitous.
The ingestion of some drugs causes hemolytic anemia in which the causative antibody can be shown to have specificity for the drug or its metabolites. Although the antibody reacts with the patient’s own RBCs, these disorders are not autoimmune disorders because the antibody does not have specificity for autoantigens. In other quite remarkable cases, ingestion of a drug causes the development of red cell autoantibodies, i.e., the antibody in the patient’s serum and in an eluate from the patient’s red cells reacts with red cells similarly to autoantibodies in idiopathic AIHAs, and no relationship between the drug and the antibody can be demonstrated in vitro. Such cases are appropriately termed drug-induced AIHAs and can be either of warm antibody or cold antibody type.
Section snippets
Incidence
Cold agglutinin syndrome (CAS) is relatively uncommon compared with warm antibody AIHA (WAIHA), but it occurs much more frequently than PCH. In a series of 347 patients with acquired immune hemolytic anemias (including drug-induced immune hemolytic anemia), 54 patients (15.6%) had CAS.2 Dacie and Worlledge3 reported that 25 percent of their patients with AIHA had CAS, whereas van Loghem et al4 and Dausset and Colombani5 reported an incidence of only 7.7%.
Age and sex
Patients with idiopathic CAS are
Incidence
Many reports emphasize that paroxysmal cold hemoglobinuria (PCH) is an unusual disease. Howard et al64 noted only two occurrences in 38 years and 298,878 admissions at the Montreal Hospital. Becker65 noted that the diagnosis was made in only I patient in 20 years at the University of Chicago clinic, during which time 130,000 patients were admitted to the hospital and 382,799 patients were seen as out-patients. Pirofsky15 encountered only 2 occurrences over a I5-year period at Bellevue Hospital
Diagnostic serologic tests for paroxysmal cold hemoglobinuria
The autoantibody associated with PCH is termed a biphasic hemolysin, that is to say, it sensitizes RBCs in the cold but only hemolyzes them when the RBCs reach 37 °C. The diagnostic test is the Donath Landsteiner (DL) test where normal RBCs are incubated with the patient’s serum at 0 °C (e.g., melting ice) and then moved to 37 °C for a further incubation. No lysis occurs following the incubation at 0 °C, and no lysis occurs if the incubation is carried out only at 37 °C. The thermal amplitude
Combined cold and warm AIHA or “Mixed” AIHA
In unusual instances, a patient will be found who has serologic findings characteristic of warm antibody AIHA while also having a cold agglutinin of high titer and thermal amplitude, thus satisfying the criteria for both warm antibody AIHA and cold agglutinin syndrome.2 Such cases are frequently referred to as “combined cold and warm AIHA” or “mixed” AIHA, and reviews of AIHA generally include such a category.88, 89, 90, 91, 92, 93
Secondary autoimmune hemolytic anemias
Autoimmune hemolytic anemias are classified as secondary for any of several reasons. One reason is the association of AIHA with an underlying disease with a frequency greater than can be explained by chance alone. For example, all authors agree that the incidence of warm antibody AIHA is higher in patients with chronic lymphocytic leukemia (CLL) and systemic lupus erythematosus (SLE) than in the general population.
Another criterion for categorizing a given case of AIHA as secondary is the
References (141)
- et al.
Classification and Clinical Characteristics of Autoimmune Hemolytic Anemias
- et al.
The serology and the prognosis of 128 cases of autoimmune hemolytic anemia
Blood
(1959) - et al.
Autoimmune hemolytic anemia in children
A review of 80 cases. Am J Med
(1974) Clinical syndromes associated with cold agglutinins
Transfus Sci
(2000)- et al.
B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins)
Am J Med
(1982) - et al.
Cutaneous necrosis at sites of transfusion: cold agglutinin disease
J Am Acad Dermatol
(1988) - et al.
Essential thrombocythemia and idiopathic cold agglutinin disease: two additional disorders associated with intravascular coagulation necrosis of the skin
J Am Acad Dermatol
(1992) Cold agglutination
Transfus Med Rev
(1989)Cold hemagglutination in acute and chronic hemolytic syndromes
Blood
(1955)- et al.
Chlorambucil treatment of patients with cold agglutinin syndrome
Blood
(1970)
Drug-Induced Immune Hemolytic Anemia
Rituximab, and anti-CD20 monoclonal antibody: history and mechanism of action
American Journal of Transplantation
Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients
Blood
Severe cold hemagglutinin disease (CHD) successfully treated with rituximab
Blood
Rapid transient reversal of anemia and long-term effects of maintenance intravenous immunoglobulin for autoimmune hemolytic anemia in patients with lymphoproliferative disorders
Am J Med
The acute and transient nature of idiopathic immune hemolytic anemia in childhood
J Pediatr
Acute paroxysmal cold hemoglobinuria
Transfus Med Rev
Autoimmune hemolysis: a critical review
Crit Rev Oncol Hematol
Hemolytic anemia associated with an ovarian tumor
Am J Med
Acquired Immune Hemolytic Anemias
Auto-immune hemolytic anemias
Serological studies in acquired hemolytic anemia
Auto-immunity and blood diseases
Practitioner
Auto-immune haemolytic anaemia (AIHA): cold-antibody syndromes. I: idiopathic types: clinical presentation and haematological and serological findings. The Haemolytic Anaemias
Autoimmune haemolytic anaemia in children
Br J Haematol
Immunopathologic and clinical features of hemolytic anemia due to cold agglutinins
Seminars Hematol
The cold hemagglutinin disease
Semin Hematol
The association of Raynaud’s phenomena, chronic haemolytic anaemia, and the formation of cold antibodies
Quart J Med
Autoimmunization and the Autoimmune Hemolytic Anemias
Cold agglutinin disease–the importance of cutaneous signs
Dermatology
Cold agglutinin disease with Raynaud’s phenomenon
Proc R Soc Med
Fulminant gangrene in transient cold agglutinemia associated with Escherichia coli infection
Can Med Assoc J
Infectious mononucleosis (glandular fever) complicated by cold agglutinins, cold urticaria and leg ulceration
Acta Derm Venereol
Cryopathic hemolytic syndromes
Cold agglutinins and the Coulter Counter Model S
Am J Clin Pathol
Spurious red-cell values with the Coulter Counter
N Engl J Med
Spurious erythrocyte indices as measured by the model S Coulter counter due to cold agglutinins
Am J Clin Pathol
Erroneous values on the Model S Coulter Counter due to high titer cold autoagglutinins
Am J Clin Pathol
Acquired Immune Hemolytic Disorders (Including Drug-Induced Immune Hemolytic Anemia)
Low-titer cold-hemagglutinin disease. Mechanism of hemolysis and response to corticosteroids
N Engl J Med
Correlation of in vivo and in vitro measurements of hemolysis in hemolytic anemia due to immune reactions
Prog Hematol
Physical properties of the red cell agglutinins in acquired hemolytic anaemia
J Exp Med
Cryoglobulinemia and Raynaud’s syndrome in a case of chronic lymphocytic leukemia
Cancer
Auto-immune haemolytic anaemias (AIHA): treatment
Essential cryoglobulinaemia and acquired haemolytic anaemia due to cold agglutinins
Australian Ann Med
Severe low-titer cold-hemagglutinin disease responsive to steroid pulse therapy
Ann Hematol
Steroid-responsive idiopathic cold agglutinin disease: a case report
Acta Haematol
Immune Haemolytic Anaemias
Immmunosuppressive drugs in the treatment of autoimmune haemolytic anaemia
Proc R Soc Med
Cold agglutinin hemolysis responding to fludarabine therapy
Am J Hematol
Cited by (135)
Bilateral retinal vasculitis associated with cold agglutinin disease treated with obinutuzumab and infliximab
2022, American Journal of Ophthalmology Case ReportsAutoimmune diseases
2022, Clinical ImmunologyParoxysmal cold hemoglobinuria in a 7-year-old male child – Was it really cold induced? A diagnostic and management dilemma
2021, Pediatric Hematology Oncology JournalA rare case report of autoimmune haemolytic anemia in a female child due to a Donath-Landsteiner antibody
2020, Transfusion Clinique et BiologiqueCitation Excerpt :PCH is a relatively uncommon form of AIHA, with studies noting an incidence of 0.001/100,000 per year in boys and 0.005/100,000 per year in girls [9]. PCH classically presents 1-2 weeks after a respiratory tract infection [5,8,11]. The anemia can be mild and self-limited or severe, requiring RBCs transfusions and treatment with corticosteroids or IVIG [8,10].
Extrinsic defects leading to increased erythrocyte destruction-immune causes
2019, Rodak’s Hematology: Clinical Principles and ApplicationsAutoimmune hemolytic anemia
2019, The Autoimmune Diseases